With FDA Hold Lifted, Avidity Works To Bring First DM1 Therapy To Market

 
• By Joseph Haas

Avidity hopes to complete enrollment in mid-2025 for an ongoing Phase III trial of its antibody-oligonucleotide conjugate in myotonic dystrophy type 1, which has no approved drug therapy.

Dystrophin, skeletal muscle cell
Avidity can go ahead with its Phase III for a rare muscular disorder • Source: Shutterstock

More from Clinical Trials

More from R&D